Coave Therapeutics
www.coavetx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coave Therapeutics
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
ChromaDex Rides Nestle Deal To 14% Q4 Growth; Mannatech, USANA End Year In Slumps
ChromaDex reports Niagen ingredient sales growth propelled by upfront minimum purchase from Nestlé Health Science; and Mannatech and USANA both reported larger full-year sales dips after ending 2022 in slumps.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- HORAMA S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice